<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ectopic pregnancy: Choosing a treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ectopic pregnancy: Choosing a treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ectopic pregnancy: Choosing a treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Togas Tulandi, MD, MHCM, FRCSC, FACOG, FCAHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3682907523"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An ectopic pregnancy is a pregnancy outside of the uterine cavity. The majority of ectopic pregnancies occur in the fallopian tube, but other possible sites include cervical, interstitial (a pregnancy located in the proximal segment of the fallopian tube that is embedded within the muscular wall of the uterus), hysterotomy scar (eg, in patients with a previous cesarean delivery or myomectomy), intramural, ovarian, or abdominal. In addition, in rare cases, a multiple gestation may be heterotopic (includes both a uterine and extrauterine pregnancy).</p><p>Ectopic pregnancy is a potentially life-threatening condition. While surgical approaches are the gold-standard treatment, advances in early diagnosis in the 1980s facilitated the introduction of medical therapy with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) [<a href="#rid1">1</a>]. With the routine use of early ultrasound, diagnosis of ectopic pregnancy can be established early, and medical treatment can be administered in most cases. The overall success rate of medical treatment in properly selected patients is nearly 90 percent [<a href="#rid2">2,3</a>]. In a limited proportion of patients with early ectopic pregnancy, expectant management is an option.</p><p>Guidance regarding how to choose a treatment for ectopic pregnancy will be reviewed here. Related topics regarding ectopic pregnancy are discussed in detail separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology, risk factors, and anatomic sites (see  <a class="medical medical_review" href="/d/html/5481.html" rel="external">"Ectopic pregnancy: Epidemiology, risk factors, and anatomic sites"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations and diagnosis (see  <a class="medical medical_review" href="/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> therapy (see  <a class="medical medical_review" href="/d/html/5407.html" rel="external">"Ectopic pregnancy: Methotrexate therapy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical management (see  <a class="medical medical_review" href="/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expectant management (see  <a class="medical medical_review" href="/d/html/5455.html" rel="external">"Ectopic pregnancy: Expectant management of tubal pregnancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis and management of nontubal ectopic or abnormally implanted intrauterine pregnancies (see  <a class="medical medical_review" href="/d/html/3283.html" rel="external">"Cervical pregnancy: Diagnosis and management"</a> and  <a class="medical medical_review" href="/d/html/132045.html" rel="external">"Abdominal pregnancy"</a> and  <a class="medical medical_review" href="/d/html/131912.html" rel="external">"Cesarean scar pregnancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pregnancy of unknown location (see  <a class="medical medical_review" href="/d/html/134770.html" rel="external">"Approach to the patient with pregnancy of unknown location"</a>)</p><p></p><p class="headingAnchor" id="H2639829578"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Management of ectopic pregnancy typically requires surgery (salpingostomy or salpingectomy) or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) treatment  (<a class="graphic graphic_algorithm graphicRef114571" href="/d/graphic/114571.html" rel="external">algorithm 1</a>). </p><p>With early diagnosis, most patients with ectopic pregnancy may be treated medically with MTX. The remaining patients will either require (eg, due to suspicion of a ruptured tube, large ectopic pregnancy, inability to comply with the follow-up for MTX therapy) or prefer surgical treatment. </p><p>A limited proportion of patients are eligible for expectant management.</p><p class="headingAnchor" id="H785308555"><span class="h1">MEDICAL VERSUS SURGICAL TREATMENT</span></p><p class="headingAnchor" id="H2976630177"><span class="h2">Choosing between methotrexate and surgery</span><span class="headingEndMark"> — </span>Medical treatment with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) for ectopic pregnancy has comparable efficacy to surgery and results in similar fertility outcomes [<a href="#rid4">4,5</a>]. (See <a class="local">'Outcomes'</a> below.)</p><p>MTX is the preferred treatment option when all of the following characteristics are present:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic stability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum beta-human chorionic gonadotropin (hCG) concentration ≤5000 mIU/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No fetal cardiac activity detected on transvaginal ultrasound (TVUS). Ectopic mass size less than 3 to 4 cm is also commonly used as a patient selection criterion; however, this has not been confirmed as a predictor of successful treatment. (See <a class="local">'Factors that may decrease efficacy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients are willing and able to comply with post-treatment follow-up and have access to emergency medical services within a reasonable time frame in case of a ruptured fallopian tube.</p><p></p><p>MTX is <strong>contraindicated</strong> and surgery is required when the following are present [<a href="#rid6">6,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic instability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intrauterine pregnancy, including a heterotopic pregnancy with coexisting viable intrauterine pregnancy. (See  <a class="medical medical_review" href="/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs or symptoms of impending or ongoing rupture of ectopic mass (eg, pelvic or abdominal pain or evidence of intraperitoneal bleeding suggestive of rupture).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinically important abnormalities in baseline hematologic, renal, or hepatic laboratory values – In such patients, surgery is recommended given that MTX can cause severe morbidity or mortality. In patients with renal insufficiency, a single dose of MTX can lead to bone marrow suppression, acute respiratory distress syndrome, bowel ischemia, or even death. Dialysis does not provide normal renal clearance [<a href="#rid8">8,9</a>]. Renal and liver disease may slow metabolism of MTX and result in pancytopenia and skin and mucosal disorders [<a href="#rid10">10</a>]. MTX, especially with chronic administration such as for those with psoriasis or rheumatoid arthritis, can be hepatotoxic. Similarly, it can cause suppression of the bone marrow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical conditions such as immunodeficiency, active pulmonary disease (eg, tuberculosis), and peptic ulcer disease – MTX can be associated with pulmonary toxicity, and the toxicities of MTX are enhanced in patients with immune impairment. Similarly, in those with peptic ulcers, MTX may worsen the condition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity to MTX.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breastfeeding.</p><p></p><p>Surgery may also be preferred by some patients who desire a concurrent surgical procedure: for example, sterilization or removal of hydrosalpinx (in a patient desiring future in vitro fertilization). Alternatively, the ectopic pregnancy may be treated with MTX, and surgery for concurrent conditions may be performed electively at a later date. (See  <a class="medical medical_review" href="/d/html/3279.html" rel="external">"Female infertility: Reproductive surgery", section on 'Salpingectomy before in vitro fertilization'</a>.)</p><p>In hemodynamically stable patients, surgical intervention should be performed <strong>only</strong> if a TVUS examination clearly shows a tubal ectopic pregnancy or an adnexal mass suggestive of ectopic pregnancy. If no mass is visualized sonographically, there is a high likelihood that a tubal pregnancy will not be visualized or palpated at surgery, thus resulting in an unnecessary surgery.</p><p>Patients may also reasonably choose surgery if they value a treatment that is of shorter duration and involves less follow-up and are willing to take the risks and recovery time associated with surgery.</p><p>Surgical contraindications are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment", section on 'Contraindications'</a>.)</p><p class="headingAnchor" id="H1371422133"><span class="h2">Methotrexate therapy</span><span class="headingEndMark"> — </span>MTX may be administered systemically (eg, intravenously, intramuscularly [IM]) as a single dose or with a multiple-dose protocol. In most cases, it is given IM as a single-dose protocol. Alternatively, MTX can be administered by direct local injection into the ectopic pregnancy sac. (See  <a class="medical medical_review" href="/d/html/5407.html" rel="external">"Ectopic pregnancy: Methotrexate therapy", section on 'Dosing and administration'</a> and  <a class="medical medical_review" href="/d/html/5407.html" rel="external">"Ectopic pregnancy: Methotrexate therapy", section on 'Comparing single- versus multi-dose therapy'</a>.)</p><p class="headingAnchor" id="H3696641142"><span class="h3">Factors that may decrease efficacy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High hCG concentration</strong> – A high serum hCG concentration is the most important factor associated with MTX treatment failure  (<a class="graphic graphic_table graphicRef74836" href="/d/graphic/74836.html" rel="external">table 1</a>). Patients with a high baseline hCG concentration (&gt;5000 mIU/mL) are more likely to require multiple courses of MTX therapy or experience treatment failure [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1">A systematic review of observational studies included 503 patients, and the outcome of single-dose MTX therapy was stratified according to initial hCG concentration [<a href="#rid11">11</a>]. There was a statistically significant increase in failure rates in patients with initial hCG levels of &gt;5000 mIU/mL compared with those who had initial levels of less than 5000 mIU/mL (odds ratio [OR] 5.5, 95% CI 3.0-9.8). The failure rate for patients who had an initial concentration between 5000 and 9999 mIU/mL was higher than for those who had initial levels between 2000 and 4999 mIU/mL (OR 3.8, 95% CI 1.2-12.3). Multiple-dose regimens were not evaluated. The authors calculated that for every 10 treatments, there would be one more failure if the hCG level is 5000 to 9999 mIU/mL than there would be if it is 2000 to 4999 mIU/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal cardiac activity</strong> – The presence of fetal cardiac activity on TVUS is another relative contraindication to medical treatment. In a meta-analysis, sonographic evidence of cardiac activity was significantly associated with treatment failure (OR 9.1, 95% CI 3.8-22.0) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large ectopic size</strong> – Although large size of the ectopic pregnancy (≥3.5 cm) is often used as a criterion for exclusion in medical treatment regimens, this restriction is based on small studies with inconsistent protocols and results [<a href="#rid12">12-14</a>]. Studies have generally restricted the use of MTX to patients with an ectopic mass less than 3 to 4 cm [<a href="#rid12">12,13</a>]; thus, there are few studies of larger masses [<a href="#rid15">15</a>]. As an example, one observational study found that the success rate for systematic MTX treatment was slightly higher for patients with ectopic masses smaller than 3.5 cm compared with masses between 3.5 and 4.0 cm (93 versus 90 percent) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">In addition, there are variations within and among studies regarding whether the size used is the actual gestational mass or the mass and surrounding hematoma [<a href="#rid12">12,13</a>]. Further, ectopic mass size does not appear to correlate with hCG level [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peritoneal fluid</strong> – The sonographic finding of free peritoneal fluid is another commonly used exclusion criterion for MTX treatment of ectopic pregnancy. Peritoneal fluid may be blood; however, this is not diagnostic of tubal rupture: peritoneal blood may also be the result of tubal abortion. Historically, culdocentesis detected blood in the peritoneal cavity of 70 to 83 percent of patients with ectopic pregnancies, but only 50 to 62 percent of them had a ruptured fallopian tube [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">In a large case series, free fluid confined to the pelvic cavity was not associated with medical treatment failure [<a href="#rid12">12</a>]. While surgical treatment of patients with free fluid in the paracolic gutters or upper abdomen may be prudent, the amount of allowable free fluid confined to the posterior cul-de-sac (pouch of Douglas) is controversial [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Preliminary reports have cited a variety of other factors that may be associated with treatment failure including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sonographic evidence of a yolk sac [<a href="#rid12">12,18,19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Isthmic location of ectopic mass (rather than ampullary) [<a href="#rid12">12,20</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High pretreatment <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> level [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rate of hCG rise or fall prior to and within several days following treatment [<a href="#rid20">20,22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thickened endometrium (eg, ≥10 or ≥12 mm) [<a href="#rid23">23-26</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Class III obesity (body mass index [BMI] ≥40 kg/m<sup>2</sup>) [<a href="#rid27">27</a>]. Compared with patients with BMI &lt;30 kg/m<sup>2</sup>, BMI ≥30 kg/m<sup>2</sup> but &lt;40 kg/m<sup>2 </sup>does not appear to be associated with higher failure rates [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H3021183296"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>When surgery is chosen, there are two options for a surgical approach: salpingectomy (removal of the fallopian tube) and salpingostomy (incising the tube to remove the tubal gestation but leaving the remainder of the tube intact). There is a small risk of retained trophoblastic tissue and an increased risk of recurrent ectopic pregnancy with salpingostomy, but both procedures appear to result in similar subsequent fertility. Traditionally, salpingectomy has been the standard procedure, but salpingostomy is preferred because it is a conservative surgical option. (See  <a class="medical medical_review" href="/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment", section on 'Salpingostomy versus salpingectomy'</a>.)</p><p class="headingAnchor" id="H206768603"><span class="h2">Outcomes</span><span class="headingEndMark"> — </span>MTX treatment for ectopic pregnancy has comparable efficacy to laparoscopic salpingostomy, avoids surgical complications, and results in similar fertility outcomes [<a href="#rid4">4,5</a>]. Studies have reported conflicting results regarding whether surgery or medical treatment is more cost-effective [<a href="#rid3">3,5</a>].</p><p class="headingAnchor" id="H1088584775"><span class="h3">Relative efficacy of methotrexate versus surgery</span><span class="headingEndMark"> — </span>MTX treatment of tubal ectopic pregnancy appears to be as effective as laparoscopic salpingostomy, as long as additional doses of MTX are administered if the follow-up hCG levels do not decrease as expected. (See  <a class="medical medical_review" href="/d/html/5407.html" rel="external">"Ectopic pregnancy: Methotrexate therapy", section on 'Comparing single- versus multi-dose therapy'</a>.)</p><p>A systematic review of randomized trials found that a single dose of systemic MTX (50 mg/m<sup>2</sup> or 1 mg/kg) was significantly less successful than laparoscopic salpingostomy (four trials, 71 versus 88 percent, relative risk [RR] 0.82, 95% CI 0.72-0.94). However, when additional doses were given if a single dose was unsuccessful, there was comparable efficacy to salpingostomy (RR 1.01, 95% CI 0.92-1.12) [<a href="#rid5">5</a>]. There was no significant difference between systemic MTX in a fixed multiple-dose regimen and surgery (one trial, 82 versus 71 percent, RR 1.15, 95% CI 0.93-1.43). In one trial, health-related quality of life was significantly more severely impaired after MTX than salpingostomy (eg, more pain, less energy) [<a href="#rid29">29</a>]. The systematic review did not address complication rates, but the trials were likely underpowered to detect rare surgical complications.</p><p class="headingAnchor" id="H1797708970"><span class="h3">Other outcomes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tubal rupture</strong> – The estimated mortality rate of ectopic pregnancy is 31.9 per 100,000 pregnancies [<a href="#rid30">30</a>]; most of these deaths are due to tubal rupture. The rate of tubal rupture depends on the population studied (rural versus urban, access to a nearby medical facility, and the availability of TVUS and serum hCG measurements). Although the rate of tubal rupture may approach 20 percent in patients who do not receive any form of treatment for their ectopic pregnancy [<a href="#rid31">31</a>], with early detection and close surveillance, the rate of tubal rupture is low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian reserve</strong> – Treatment with MTX does not appear to compromise ovarian reserve [<a href="#rid32">32</a>]. In a study of patients treated with in vitro fertilization, ovarian responses among patients with a history of ectopic pregnancy treated with MTX or salpingectomy were comparable [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertility rates</strong> – It appears that the fertility rates after treatment of ectopic pregnancy with salpingostomy, salpingectomy, or MTX are similar. In the systematic review of randomized trials, subsequent fertility outcomes were reported in 98 patients [<a href="#rid5">5</a>]. No significant differences were found between single-dose MTX and salpingostomy in the number of intrauterine pregnancies (RR 1.01, 95% CI 0.66-1.54) or in recurrent ectopic pregnancy (RR 0.63, 95% CI 0.14-2.77). Ectopic pregnancy is likely associated with subfertility since extrauterine pregnancy is usually due to altered tubal function secondary to clinical or subclinical salpingitis. In a subsequent randomized trial of 446 patients assigned to salpingostomy or salpingectomy, the cumulative ongoing pregnancy rates after 36 months were comparable [<a href="#rid35">35</a>]. A study suggested that patients with ectopic first pregnancies had an increased risk of preterm birth (95% CI 1.18-1.37), low birth weight (95% CI 1.1-1.31), placental abruption (95% CI 1.04-1.41), and placenta previa (95% CI 1.1-1.91) [<a href="#rid36">36</a>]. The risk of placental abruption was particularly higher in older patients with a prior ectopic pregnancy (RR 1.42, 95% CI 1.16-1.69).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent ectopic pregnancy</strong> – The risk of another ectopic pregnancy appears to be the same for both medical and surgical therapies [<a href="#rid37">37</a>]. (See <a class="local">'Medical versus surgical treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H2508848316"><span class="h1">MEDICAL VERSUS EXPECTANT MANAGEMENT</span><span class="headingEndMark"> — </span>Expectant management is an option only for a small proportion of patients with suspected ectopic pregnancy and a very low risk of tubal rupture. This includes patients with the following  (<a class="graphic graphic_algorithm graphicRef114571" href="/d/graphic/114571.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>No symptoms (eg, vaginal bleeding, abdominal pain) or signs of impending rupture</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirmed or suspected tubal ectopic pregnancy on transvaginal ultrasound (TVUS); findings may include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A complex inhomogeneous extraovarian adnexal mass</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An extraovarian adnexal mass containing an empty gestational sac</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An extrauterine gestational sac with a yolk sac or embryo (<strong>without</strong> a heartbeat)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum beta-human chorionic gonadotropin concentration is low (≤200 mIU/mL) <strong>and</strong> declining.</p><p></p><p class="bulletIndent1">We define declining as a decrease of &gt;10 percent across two consecutive measurements. While higher thresholds (eg, 1000 to 2000 mIU/mL) have been studied [<a href="#rid38">38-40</a>], and some guidelines advise offering expectant management to patients who meet the above criteria and have an hCG &lt;2000 mIU/mL [<a href="#rid41">41,42</a>], we recommend that more stringent hCG criterion (ie, ≤200 mIU/mL) be used given that ectopic pregnancy is a potentially life-threatening condition, and treatments for ectopic pregnancy (ie, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [MTX], surgery) are safe and effective [<a href="#rid4">4</a>]. (See <a class="local">'Relative efficacy of methotrexate versus surgery'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Willing and able to attend posttreatment follow-up appointments and have access to emergency medical services within a reasonable time frame in case of a ruptured fallopian tube.</p><p></p><p>Our protocol for following such patients is described in detail separately. (See  <a class="medical medical_review" href="/d/html/5455.html" rel="external">"Ectopic pregnancy: Expectant management of tubal pregnancy", section on 'Clinical protocol'</a>.)</p><p>In patients with a strong suspicion of ectopic pregnancy and no possibility of an intrauterine pregnancy, a single dose of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> has minimal side effects.</p><p class="headingAnchor" id="H1814210956"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H3642364912"><span class="h2">Heterotopic pregnancy</span><span class="headingEndMark"> — </span>In patients with a heterotopic pregnancy in whom the intrauterine gestation is live and desired, systemic medical therapy (ie, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [MTX]) is contraindicated [<a href="#rid43">43</a>].</p><p>In such patients, treatment should be tailored to the site of implantation of the ectopic pregnancy, utilize the least invasive therapy, and preserve the concomitant intrauterine pregnancy.</p><p class="bulletIndent1"><span class="glyph">●</span>Salpingectomy is the standard surgical approach for a coexistent tubal pregnancy and should be the first line of treatment in patients with hemodynamic instability or other signs of tubal rupture [<a href="#rid44">44,45</a>]. A laparoscopic approach is desirable if the patient is hemodynamically stable. (See  <a class="medical medical_review" href="/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In expert hands, an unruptured ectopic pregnancy can alternatively be treated with local feticidal injection under sonographic guidance. Substances for injection should have high therapeutic effectiveness with low toxicity for the concurrent intrauterine pregnancy and produce no lasting damage to the fallopian tube [<a href="#rid46">46</a>]. Two options are <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a> (KCl; eg, 2 mL of 2 mEq/mL [<a href="#rid47">47</a>]) and hyperosmolar glucose [<a href="#rid46">46,47</a>].</p><p></p><p class="bulletIndent1">In a literature review including 11 cases of heterotopic tubal and intrauterine pregnancy treated with KCl injection, 6 of 11 cases (55 percent) failed this therapy and required surgical intervention [<a href="#rid44">44</a>].</p><p></p><p>With either approach, an ultrasound examination to confirm cardiac activity of the intrauterine fetus is performed one to two weeks after the procedure.</p><p>There appears to be a higher risk of spontaneous abortion of the intrauterine pregnancy of a heterotopic pregnancy than in an isolated intrauterine pregnancy [<a href="#rid43">43,45,48</a>].</p><p class="headingAnchor" id="H809750011"><span class="h2">Other abnormally implanted pregnancies</span><span class="headingEndMark"> — </span>Medical and surgical management of other abnormally implanted (eg, interstitial, cervical, cesarean scar, abdominal) pregnancies are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5407.html" rel="external">"Ectopic pregnancy: Methotrexate therapy", section on 'Patients with an interstitial pregnancy: Multiple-dose'</a> and  <a class="medical medical_review" href="/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment", section on 'Interstitial pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3283.html" rel="external">"Cervical pregnancy: Diagnosis and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/131912.html" rel="external">"Cesarean scar pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/132045.html" rel="external">"Abdominal pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H1050185893"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118506.html" rel="external">"Society guideline links: Ectopic pregnancy"</a>.)</p><p class="headingAnchor" id="H3550399213"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15856.html" rel="external">"Patient education: Ectopic pregnancy (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/6723.html" rel="external">"Patient education: Ectopic (tubal) pregnancy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H4108436297"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An ectopic pregnancy is an extrauterine pregnancy. Almost all ectopic pregnancies occur in the fallopian tube. Tubal ectopic pregnancy may be treated medically (<a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [MTX]), surgically, or in a small proportion of patients with expectant management  (<a class="graphic graphic_algorithm graphicRef114571" href="/d/graphic/114571.html" rel="external">algorithm 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with tubal pregnancy who are candidates for MTX therapy, we suggest MTX rather than surgical treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Medical versus surgical treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients requiring surgery</strong> – Surgery is required for patients with the following characteristics (see <a class="local">'Choosing between methotrexate and surgery'</a> above and <a class="local">'Surgery'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamically unstable</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected or impending tubal rupture (eg, evidence of intraperitoneal bleeding, pelvic or abdominal pain)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heterotopic pregnancy with coexisting viable intrauterine pregnancy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Contraindications to MTX therapy or failed MTX therapy</p><p></p><p class="bulletIndent1">Patients may also reasonably choose surgery if they need a concurrent surgical procedure or if they value a treatment that is of shorter duration and involves less follow-up and are willing to take the risks and recovery time associated with surgery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for MTX </strong>– Candidates for MTX treatment are patients with ectopic pregnancy who meet the following criteria (see <a class="local">'Choosing between methotrexate and surgery'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamically stable</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Have no renal, hepatic, or hematologic disorders</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Able and willing to attend post-treatment appointments and have access to medical care in case of a ruptured fallopian tube</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pretreatment serum human chorionic gonadotropin (hCG) concentration ≤5000 mIU/mL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No fetal cardiac activity on transvaginal ultrasound</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that may decrease efficacy of MTX</strong> – Factors that may decrease the efficacy of MTX treatment of ectopic pregnancy include hCG &gt;5000 mIU/mL, large ectopic size (eg, ≥3.5 cm), presence of fetal cardiac activity, and sonographic finding of peritoneal fluid. (See <a class="local">'Factors that may decrease efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of expectant management</strong> – Expectant management is an option only for a small proportion of patients with ectopic pregnancy and a very low risk of tubal rupture. Generally accepted criteria for expectant management include (see <a class="local">'Medical versus expectant management'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No symptoms or signs of impending rupture (eg, pelvic or abdominal pain)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Confirmed or suspected tubal pregnancy on TVUS (without cardiac activity) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>hCG is low and declining (variable thresholds are used, as discussed below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient can comply with close follow-up and has ready access to emergency surgical treatment, if necessary</p><p></p><p class="bulletIndent1">For patients who otherwise meet these criteria but have a serum hCG is &gt;200 mIU/mL, we suggest MTX or surgery<strong> </strong>rather than expectant management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Other experts offer expectant management to patients who meet the above criteria and have an hCG &lt;2000 mIU/mL. (See <a class="local">'Medical versus expectant management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lipscomb GH. Medical therapy for ectopic pregnancy. Semin Reprod Med 2007; 25:93.</a></li><li><a class="nounderline abstract_t">Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol 2003; 101:778.</a></li><li><a class="nounderline abstract_t">Morlock RJ, Lafata JE, Eisenstein D. Cost-effectiveness of single-dose methotrexate compared with laparoscopic treatment of ectopic pregnancy. Obstet Gynecol 2000; 95:407.</a></li><li><a class="nounderline abstract_t">Hajenius PJ, Mol F, Mol BW, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2007; :CD000324.</a></li><li><a class="nounderline abstract_t">Mol F, Mol BW, Ankum WM, et al. Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Update 2008; 14:309.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 94: Medical management of ectopic pregnancy. Obstet Gynecol 2008; 111:1479.</a></li><li><a class="nounderline abstract_t">Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril 2013; 100:638.</a></li><li><a class="nounderline abstract_t">Kelly H, Harvey D, Moll S. A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstet Gynecol 2006; 107:439.</a></li><li><a class="nounderline abstract_t">Teal SB. A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstet Gynecol 2006; 107:1420.</a></li><li><a class="nounderline abstract_t">Willner N, Storch S, Tadmor T, Schiff E. Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy. Eur J Clin Pharmacol 2014; 70:261.</a></li><li><a class="nounderline abstract_t">Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007; 87:481.</a></li><li><a class="nounderline abstract_t">Lipscomb GH, McCord ML, Stovall TG, et al. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 1999; 341:1974.</a></li><li><a class="nounderline abstract_t">Lipscomb GH, Bran D, McCord ML, et al. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol 1998; 178:1354.</a></li><li><a class="nounderline abstract_t">Nazac A, Gervaise A, Bouyer J, et al. Predictors of success in methotrexate treatment of women with unruptured tubal pregnancies. Ultrasound Obstet Gynecol 2003; 21:181.</a></li><li><a class="nounderline abstract_t">Tzafettas JM, Stephanatos A, Loufopoulos A, et al. Single high dose of local methotrexate for the management of relatively advanced ectopic pregnancies. Fertil Steril 1999; 71:1010.</a></li><li><a class="nounderline abstract_t">Gamzu R, Almog B, Levin Y, et al. The ultrasonographic appearance of tubal pregnancy in patients treated with methotrexate. Hum Reprod 2002; 17:2585.</a></li><li><a class="nounderline abstract_t">Vermesh M, Graczykowski JW, Sauer MV. Reevaluation of the role of culdocentesis in the management of ectopic pregnancy. Am J Obstet Gynecol 1990; 162:411.</a></li><li><a class="nounderline abstract_t">Bixby S, Tello R, Kuligowska E. Presence of a yolk sac on transvaginal sonography is the most reliable predictor of single-dose methotrexate treatment failure in ectopic pregnancy. J Ultrasound Med 2005; 24:591.</a></li><li><a class="nounderline abstract_t">Potter MB, Lepine LA, Jamieson DJ. Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital. Am J Obstet Gynecol 2003; 188:1192.</a></li><li><a class="nounderline abstract_t">Dudley PS, Heard MJ, Sangi-Haghpeykar H, et al. Characterizing ectopic pregnancies that rupture despite treatment with methotrexate. Fertil Steril 2004; 82:1374.</a></li><li><a class="nounderline abstract_t">Takacs P, Rodriguez L. High folic acid levels and failure of single-dose methotrexate treatment in ectopic pregnancy. Int J Gynaecol Obstet 2005; 89:301.</a></li><li><a class="nounderline abstract_t">da Costa Soares R, Elito J Jr, Camano L. Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate. Arch Gynecol Obstet 2008; 278:319.</a></li><li><a class="nounderline abstract_t">da Costa Soares R, Elito J Jr, Han KK, Camano L. Endometrial thickness as an orienting factor for the medical treatment of unruptured tubal pregnancy. Acta Obstet Gynecol Scand 2004; 83:289.</a></li><li><a class="nounderline abstract_t">Takacs P, Chakhtoura N, De Santis T, Verma U. Evaluation of the relationship between endometrial thickness and failure of single-dose methotrexate in ectopic pregnancy. Arch Gynecol Obstet 2005; 272:269.</a></li><li><a class="nounderline abstract_t">Levine Y, Yahav L, Schwarzman P, et al. The correlation between endometrial thickness and the criteria for MTX treatment for ectopic pregnancy. J Obstet Gynaecol 2021; 41:1230.</a></li><li><a class="nounderline abstract_t">Fang T, Chen M, Yu W, et al. The predictive value of endometrial thickness in 3117 fresh IVF/ICSI cycles for ectopic pregnancy. J Gynecol Obstet Hum Reprod 2021; 50:102072.</a></li><li><a class="nounderline abstract_t">Hoyos LR, Malik M, Najjar M, et al. Morbid obesity and outcome of ectopic pregnancy following capped single-dose regimen methotrexate. Arch Gynecol Obstet 2017; 295:375.</a></li><li><a class="nounderline abstract_t">Levin G, Meyer R, Dior U, et al. Outcome of methotrexate treatment for ectopic pregnancies among obese women. J Gynecol Obstet Hum Reprod 2020; :101790.</a></li><li><a class="nounderline abstract_t">Nieuwkerk PT, Hajenius PJ, Ankum WM, et al. Systemic methotrexate therapy versus laparoscopic salpingostomy in patients with tubal pregnancy. Part I. Impact on patients' health-related quality of life. Fertil Steril 1998; 70:511.</a></li><li><a class="nounderline abstract_t">Grimes DA. Estimation of pregnancy-related mortality risk by pregnancy outcome, United States, 1991 to 1999. Am J Obstet Gynecol 2006; 194:92.</a></li><li><a class="nounderline abstract_t">Job-Spira N, Fernandez H, Bouyer J, et al. Ruptured tubal ectopic pregnancy: risk factors and reproductive outcome: results of a population-based study in France. Am J Obstet Gynecol 1999; 180:938.</a></li><li><a class="nounderline abstract_t">Oriol B, Barrio A, Pacheco A, et al. Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve. Fertil Steril 2008; 90:1579.</a></li><li><a class="nounderline abstract_t">Wiser A, Gilbert A, Nahum R, et al. Effects of treatment of ectopic pregnancy with methotrexate or salpingectomy in the subsequent IVF cycle. Reprod Biomed Online 2013; 26:449.</a></li><li><a class="nounderline abstract_t">Gay C, Perrin J, Courbiere B, et al. Impact of salpingectomy for ectopic pregnancy on the ovarian response during IVF stimulation. J Gynecol Obstet Hum Reprod 2019; 48:727.</a></li><li><a class="nounderline abstract_t">Mol F, Strandell A, Jurkovic D, et al. The ESEP study: salpingostomy versus salpingectomy for tubal ectopic pregnancy; the impact on future fertility: a randomised controlled trial. BMC Womens Health 2008; 8:11.</a></li><li><a class="nounderline abstract_t">Chouinard M, Mayrand MH, Ayoub A, et al. Ectopic pregnancy and outcomes of future intrauterine pregnancy. Fertil Steril 2019; 112:112.</a></li><li><a class="nounderline abstract_t">Gervaise A, Masson L, de Tayrac R, et al. Reproductive outcome after methotrexate treatment of tubal pregnancies. Fertil Steril 2004; 82:304.</a></li><li><a class="nounderline abstract_t">Korhonen J, Stenman UH, Ylöstalo P. Low-dose oral methotrexate with expectant management of ectopic pregnancy. Obstet Gynecol 1996; 88:775.</a></li><li><a class="nounderline abstract_t">Trio D, Strobelt N, Picciolo C, et al. Prognostic factors for successful expectant management of ectopic pregnancy. Fertil Steril 1995; 63:469.</a></li><li><a class="nounderline abstract_t">van Mello NM, Mol F, Verhoeve HR, et al. Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison. Hum Reprod 2013; 28:60.</a></li><li><a class="nounderline abstract_t">Webster K, Eadon H, Fishburn S, et al. Ectopic pregnancy and miscarriage: diagnosis and initial management: summary of updated NICE guidance. BMJ 2019; 367:l6283.</a></li><li class="breakAll">Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE guideline [NG126]. National Institute for Health Care Excellence. April 2019. https://www.nice.org.uk/guidance/ng126/chapter/Recommendations#management-of-miscarriage (Accessed on March 03, 2021).</li><li><a class="nounderline abstract_t">Louis-Sylvestre C, Morice P, Chapron C, Dubuisson JB. The role of laparoscopy in the diagnosis and management of heterotopic pregnancies. Hum Reprod 1997; 12:1100.</a></li><li><a class="nounderline abstract_t">Goldstein JS, Ratts VS, Philpott T, Dahan MH. Risk of surgery after use of potassium chloride for treatment of tubal heterotopic pregnancy. Obstet Gynecol 2006; 107:506.</a></li><li><a class="nounderline abstract_t">Barrenetxea G, Barinaga-Rementeria L, Lopez de Larruzea A, et al. Heterotopic pregnancy: two cases and a comparative review. Fertil Steril 2007; 87:417.e9.</a></li><li><a class="nounderline abstract_t">Goldberg JM, Bedaiwy MA. Transvaginal local injection of hyperosmolar glucose for the treatment of heterotopic pregnancies. Obstet Gynecol 2006; 107:509.</a></li><li><a class="nounderline abstract_t">Salomon LJ, Fernandez H, Chauveaud A, et al. Successful management of a heterotopic Caesarean scar pregnancy: potassium chloride injection with preservation of the intrauterine gestation: case report. Hum Reprod 2003; 18:189.</a></li><li><a class="nounderline abstract_t">Clayton HB, Schieve LA, Peterson HB, et al. A comparison of heterotopic and intrauterine-only pregnancy outcomes after assisted reproductive technologies in the United States from 1999 to 2002. Fertil Steril 2007; 87:303.</a></li></ol></div><div id="topicVersionRevision">Topic 112852 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377896" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Medical therapy for ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681886" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711553" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cost-effectiveness of single-dose methotrexate compared with laparoscopic treatment of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253448" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Interventions for tubal ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18522946" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515537" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : ACOG Practice Bulletin No. 94: Medical management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849842" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Medical treatment of ectopic pregnancy: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449141" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738176" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24276413" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173905" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607814" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9662322" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601843" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Predictors of success in methotrexate treatment of women with unruptured tubal pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360902" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Single high dose of local methotrexate for the management of relatively advanced ectopic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351533" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The ultrasonographic appearance of tubal pregnancy in patients treated with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137966" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Reevaluation of the role of culdocentesis in the management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840789" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Presence of a yolk sac on transvaginal sonography is the most reliable predictor of single-dose methotrexate treatment failure in ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748475" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533363" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Characterizing ectopic pregnancies that rupture despite treatment with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919408" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High folic acid levels and failure of single-dose methotrexate treatment in ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18274766" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14995926" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Endometrial thickness as an orienting factor for the medical treatment of unruptured tubal pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16001188" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of the relationship between endometrial thickness and failure of single-dose methotrexate in ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33616483" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The correlation between endometrial thickness and the criteria for MTX treatment for ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33508484" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The predictive value of endometrial thickness in 3117 fresh IVF/ICSI cycles for ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27844211" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Morbid obesity and outcome of ectopic pregnancy following capped single-dose regimen methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32413523" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Outcome of methotrexate treatment for ectopic pregnancies among obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9757881" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Systemic methotrexate therapy versus laparoscopic salpingostomy in patients with tubal pregnancy. Part I. Impact on patients' health-related quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16389015" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Estimation of pregnancy-related mortality risk by pregnancy outcome, United States, 1991 to 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10203662" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ruptured tubal ectopic pregnancy: risk factors and reproductive outcome: results of a population-based study in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18054933" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518030" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of treatment of ectopic pregnancy with methotrexate or salpingectomy in the subsequent IVF cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31108239" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of salpingectomy for ectopic pregnancy on the ovarian response during IVF stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18582372" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The ESEP study: salpingostomy versus salpingectomy for tubal ectopic pregnancy; the impact on future fertility: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31056305" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ectopic pregnancy and outcomes of future intrauterine pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302275" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reproductive outcome after methotrexate treatment of tubal pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8885912" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Low-dose oral methotrexate with expectant management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7851572" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prognostic factors for successful expectant management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23081873" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31722871" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ectopic pregnancy and miscarriage: diagnosis and initial management: summary of updated NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31722871" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ectopic pregnancy and miscarriage: diagnosis and initial management: summary of updated NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9194674" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The role of laparoscopy in the diagnosis and management of heterotopic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449166" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk of surgery after use of potassium chloride for treatment of tubal heterotopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074353" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Heterotopic pregnancy: two cases and a comparative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449167" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Transvaginal local injection of hyperosmolar glucose for the treatment of heterotopic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525465" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Successful management of a heterotopic Caesarean scar pregnancy: potassium chloride injection with preservation of the intrauterine gestation: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113092" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A comparison of heterotopic and intrauterine-only pregnancy outcomes after assisted reproductive technologies in the United States from 1999 to 2002.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
